CVE:AQS Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis C$0.0050 0.00 (-37.50%) As of 04/25/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Aequus Pharmaceuticals Stock (CVE:AQS) Get Aequus Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$0.01▼C$0.0150-Day RangeC$0.01▼C$0.0152-Week RangeC$0.01▼C$0.04Volume100,000 shsAverage Volume162,442 shsMarket CapitalizationC$663.15 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada. Read More Receive AQS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQS Stock News HeadlinesAequus Pharmaceuticals Welcomes Giovanni Di Genova to Board of DirectorsSeptember 22 at 5:10 PM | tipranks.comAequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)January 22, 2025 | theglobeandmail.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 23 at 2:00 AM | Banyan Hill Publishing (Ad)Aequus Pharmaceuticals Reports Revenue Growth Amid RestructuringNovember 9, 2024 | markets.businessinsider.comAequus Pharmaceuticals Inc. (AQSZF)September 5, 2024 | finance.yahoo.comAequus Pharmaceuticals Inc (AQS)August 3, 2024 | investing.comClosing Bell: Aequus Pharmaceuticals Inc down on Friday (AQS)July 23, 2024 | theglobeandmail.comAequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)May 2, 2024 | finance.yahoo.comSee More Headlines AQS Stock Analysis - Frequently Asked Questions How have AQS shares performed this year? Aequus Pharmaceuticals' stock was trading at C$0.01 at the start of the year. Since then, AQS stock has decreased by 50.0% and is now trading at C$0.01. How do I buy shares of Aequus Pharmaceuticals? Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aequus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aequus Pharmaceuticals investors own include Growlife (PHOT), Unrivaled Brands (TRTC), Acorn Energy (ACFN), Crown Castle (CCI), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Rogers (ROG). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:AQS CIKN/A Webwww.aequuspharma.ca Phone+1-604-3367906FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,569.60% Return on Assets-178.79% Debt Debt-to-Equity Ratio138.88 Current Ratio0.07 Quick Ratio0.46 Sales & Book Value Annual SalesC$1.17 million Price / Sales0.57 Cash FlowC$0.00 per share Price / Cash Flow5.00 Book ValueC($0.04) per share Price / Book-0.13Miscellaneous Outstanding Shares132,630,000Free FloatN/AMarket CapC$663.15 thousand OptionableNot Optionable Beta-0.02 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (CVE:AQS) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aequus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.